A Study of BNT329 in People With Solid Tumors

Full Title

First-in-Human, Open-Label, Multi-Site, Phase I/IIa, Dose Escalation Trial with Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants with Advanced Solid Tumors Known to Express CA19-9

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Eileen O’Reilly’s office at 646-888-4182.

Protocol
26-076
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Relapsed or Refractory
Investigator
Eileen M. O'Reilly
Co-Investigators
Kenneth H. Yu
Diseases
Colorectal Cancer
Endometrial and other Uterine Cancers › Endometrial Cancer
Gynecologic Cancer › Ovarian Cancer
Upper Gastrointestinal › Esophageal Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07186842
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description